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Fiona Yull2,3† and Dineo Khabele1,3†Abstract
Background: Nuclear factor-kappa B (NF-kappaB) signaling is an important link between inflammation and
peritoneal carcinomatosis in human ovarian cancer. Our objective was to track NF-kappaB signaling during ovarian
cancer progression in a syngeneic mouse model using tumor cells stably expressing an NF-kappaB reporter.
Methods: ID8 mouse ovarian cancer cells stably expressing an NF-kappaB-dependent GFP/luciferase (NGL)
fusion reporter transgene (ID8-NGL) were generated, and injected intra-peritoneally into C57BL/6 mice. NGL
reporter activity in tumors was non-invasively monitored by bioluminescence imaging and measured in
luciferase assays in harvested tumors. Ascites fluid or peritoneal lavages were analyzed for inflammatory cell and
macrophage content, and for mRNA expression of M1 and M2 macrophage markers by quantitative real-time
RT-PCR. 2-tailed Mann-Whitney tests were used for measuring differences between groups in in vivo
experiments.
Results: In ID8-NGL cells, responsiveness of the reporter to NF-kappaB activators and inhibitors was confirmed
in vitro and in vivo. ID8-NGL tumors in C57BL/6 mice bore histopathological resemblance to human high-grade
serous ovarian cancer and exhibited similar peritoneal disease spread. Tumor NF-kappaB activity, measured by
the NGL reporter and by western blot of nuclear p65 expression, was markedly elevated at late stages of ovarian
cancer progression. In ascites fluid, macrophages were the predominant inflammatory cell population. There
were elevated levels of the M2-like pro-tumor macrophage marker, mannose-receptor, during tumor
progression, and reduced levels following NF-kappaB inhibition with thymoquinone.
Conclusions: Our ID8-NGL reporter syngeneic model is suitable for investigating changes in tumor NF-kappaB
activity during ovarian cancer progression, how NF-kappaB activity influences immune cells in the tumor
microenvironment, and effects of NF-kappaB-targeted treatments in future studies.
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Ovarian cancer is the most lethal gynecologic malignancy
in the United States [1]. Most women diagnosed with
epithelial ovarian cancers have advanced, metastatic disease
characterized by abdominal ascites and peritoneal carcin-
omatosis [2]. Inflammation is a hallmark of cancer [3],* Correspondence: andrew.j.wilson@vanderbilt.edu
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stated.and there is ample evidence linking chronic inflammation
to pro-tumorigenic effects in ovarian cancer development
and progression [4-9]. Pro-inflammatory cytokines and
chemokines produced by peritoneal macrophages con-
tribute to the distinct clinical features of ovarian cancer,
specifically malignant ascites and widespread peritoneal
tumor implants [4,10,11].
The nuclear factor-kappaB (NF-κB) pathway is a critical
molecular link between inflammation and cancer. NF-κB
signaling is known to play an important role in severalLtd. This is an Open Access article distributed under the terms of the Creative
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are five known NF-κB subunits in humans: NF-κB 1
(p105/p50), NF-κB 2 (p100/p52), RelA (p65), RelB and
c-Rel [17]. In a quiescent state, NF-κB subunits are bound
to inhibitors of κB protein (IκBs) and are sequestered in
the cytoplasm. Activation of the classical NF-κB cascade
is initiated by growth factors, microbes, cytokines and
genotoxic stress, which in turn activate the IκB kinase
(IKK) complex. Activated IKK phosphorylates IκBα,
which is then ubiquitinated. As a result, the p50-RelA
dimer translocates to the nucleus, where it binds to the
promoter/enhancer regions of genes involved in the
regulation of cell growth, apoptosis and inflammation [16].
Several lines of evidence link NF-κB activity to ovarian
cancer progression. Constitutive activation of NF-κB is
observed in a large subset of ovarian tumors and is
associated with tumor growth and hallmarks of progres-
sion [4,13-16]. Moreover, NF-κB is known to link a specific
subset of pro-inflammatory cytokines and chemokines,
including a TNF cytokine network, to human epithelial
ovarian cancer [6,10,15,18]. Such functions of NF-κB have
led to successful preclinical testing of NF-κB inhibitors in
ovarian cancer model systems, for example thymoquinone,
a product of the medicinal plant Nigella sativa [19].
However, most preclinical models are limited by the fact
that drug effects are tested on cancer cells in the absence
of the supporting tumor microenvironment, essential for
cancer progression in vivo.
Ovarian tumors are known to polarize macrophages
to display pro-tumorigenic characteristics in a NF-κB-
dependent manner [4,20]. Classically activated or cytotoxic
anti-tumorigenic macrophages (also called M1) and
“alternatively” activated pro-tumorigenic macrophages
(M2) represent two extremes in the spectrum of the
macrophage phenotype [21]. This polarization is part of a
complex interplay of signaling and responses between
tumor cells and inflammatory cells such as macrophages, T
cells and dendritic cells [22-24]. Despite current knowledge,
substantial gaps remain regarding the specific influence of
NF-κB activation in the peritoneum during ovarian tumor
dissemination.
Herein, we describe the generation of mouse ID8 ovarian
cancer cells stably expressing a green fluorescent protein
(GFP)/luciferase fusion product under the control of a
synthetic NF-κB-dependent promoter [25,26]. These
reporter cells allow the intra-vital mapping of NF-κB
activity during tumor progression in a syngeneic mouse
model of ovarian cancer. Successful generation of this
model provides unique insight into the role of NF-κB acti-
vation in different phases of ovarian cancer progression,
effects of modulating NF-κB activity on host cell immune
responses in the tumor microenvironment, and will serve
as a powerful tool for pre-clinical testing of agents that
target NF-κB in ovarian cancer.Materials and methods
Generation of ID8-NGL cells
Mouse epithelial ovarian cancer (ID8) cells are a well-
established cell line derived from C57BL/6 mice that
are routinely used in syngeneic mouse models of ovarian
cancer [4,11,27,28]. Here, we have generated ID8 cells
stably expressing an NF-κB-dependent reporter plasmid,
termed ID8-NGL. To generate the NGL plasmid, four tan-
dem copies of the 36-base enhancer from the 5′ HIV-long
terminal repeat, each containing two NF-κB binding sites
GGGACTTTCC, were cloned into the pEGFPluc vector
backbone [25,26] (Figure 1A).
The NGL plasmid was transfected into ID8 cells
according to manufacturer’s instructions using Lipofec-
tamine 2000 (Invitrogen, Carlsbad, CA). Clones with
genomic incorporation of plasmid DNA were selected by
growth in 10% fetal bovine serum (FBS)-supplemented
DMEM High-Glucose medium (Invitrogen) with 400 μg/
ml G418 (Sigma Chemical Co., St Louis, MO). Clones were
selected using an inverted light microscope and initially
tested for NGL expression in luciferase assays. Further
validation of ID8-NGL clones with basal luciferase activity
greater than 1×106 RLU/mg protein was performed by
bioluminescence imaging of cell cultures and Western
Blot detection of GFP expression.
The ID8-NGL clone selected for in vivo experiments was
cultured in 10% FBS-supplemented DMEM High-Glucose
medium with 400 μg/ml G418, and passaged by standard
techniques. Parental ID8 cells and lung epithelial cells
stably transfected with the NGL plasmid (A549-NGL), a
kind gift of Dr. Timothy Blackwell (Vanderbilt University,
Nashville, TN) [29], were used for comparison in these
characterization studies. Finally, we confirmed that the
ID8-NGL clone selected responded appropriately to
classical activators of NF-κB signaling, TNF-α and IL-1β
(R&D Systems, Minneapolis, MN), and the NF-κB inhibitor,
thymoquinone (Sigma).
Animal model and drug treatment
Wild-type C57BL/6 mice were injected intra-peritoneally
(IP) with 1x107 ID8-NGL cells in 200 μl PBS or mock-
injected with an equal volume of sterile PBS. 21 gauge
safety hypodermic needles (Becton, Dickinson and Com-
pany, Franklin Lakes, NJ) were used for these injections.
Tumor cells were allowed to grow in mice for up to 90 days
before humane sacrifice. A subset of mice underwent
bioluminescence imaging at defined time points. At 30 days
after ID8-NGL injection, a subset of mice (5 per group)
was randomly selected to receive thrice weekly 20 mg/kg
thymoquinone or PBS vehicle by IP injection for 10 days
[30]. No signs of drug toxicity were observed in the
TQ-treated mice.
Tumor progression was also monitored by body weight
and abdominal girth measurements. At time of sacrifice,
Figure 1 Characterization of ID8-NGL cells. (A) Schematic diagram of the pEGFPluc NGL reporter plasmid. The plasmid contains 4 tandem
copies of a 36 base pair enhancer of the HIV long terminal repeat, which contains 2 consensus NF-κB binding sites (blue). Basal NF-κB reporter
activity in ID8-NGL cells compared to parental ID8 cells was measured in (B) luciferase assays from protein extracts and (C) by bioluminescence
imaging of cell monolayers. (D) Western blot showing GFP expression in ID8-NGL cells not observed in parental ID8 cells. Actin was used as the
loading control. (E) Stimulatory effect of a 4 h treatment with TNF-α and IL-1β (both 10 ng/ml) on luciferase activity in protein extracts from
ID8-NGL cells. (F) Western blot showing the stimulatory effect of TNF-α on GFP and p-IκB expression after 4 h is inhibited by 2 hours’ pre-treatment
with the NF-κB inhibitor, thymoquinone (50 μM). Bioluminescent imaging is also shown. (G) Stimulatory effect of TNF-α on luciferase activity was also
inhibited by thymoquinone (50 μM). Values are mean + SD of 3 independent experiments. * p < 0.01 relative to Control, # p < 0.01 relative to TNF
alone, both Student’s t test.
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syringe, and volume measured. If no measurable ascites
was present, peritoneal lavages were performed by injecting
8 ml PBS intra-peritoneally and carefully extracting the
fluid with a hypodermic syringe. Tumor implants in the
peritoneal wall and the mesentery were harvested and
snap frozen or formalin-fixed for further analysis. The
experimental protocol was reviewed and approved by
the Institutional Animal Care and Use Committee at
Vanderbilt University.
Luciferase assays
Luciferase activity was measured in harvested tumors
following tissue homogenization in 1 ml passive lysis buffer,
and in whole cell protein extracts from cells grown in vitro,using the Promega Luciferase Assay system (Madison,
WI). Activity was analyzed using a GloMax Luminometer
(Promega). Results were expressed as relative light units
(RLU) normalized for protein content, as measured by the
Bradford assay (Bio-Rad, Hercules, CA).
Bioluminescence imaging
Mice were anesthetized and luciferin (Biosynth AG,
Rietlistr, Switzerland) administered by retro-orbital injec-
tion (1 mg/mouse in 100 μl isotonic saline). Mice were
imaged using a Xenogen IVIS 2000 imaging device
(Caliper Life Sciences., Hopkinton, MA). Light emission
was detected by an ICCD camera and quantified using
image processing Living Image v 2.5 software (Caliper Life
Sciences). For bioluminescence of cell cultures, a final
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just prior to imaging with the Xenogen IVIS 2000.
Analysis of ascites/peritoneal lavage fluid
Ascites or peritoneal lavage fluid was centrifuged at
1500 rpm for 5 minutes to separate cells from supernatant.
Where applicable, red blood cells were lysed by ACK lysing
buffer according to manufacturer’s instructions (Invitrogen,
Carlsbad, CA). An aliquot of cells were suspended in PBS
with 1% BSA for total cell counts using a grid haemocyt-
ometer. Cells were then either snap-frozen for RNA extrac-
tion, or centrifuged onto microscope slides using a Thermo
Cytospin II Cytocentrifuge (500 rpm for 10 minutes) for
differential counts of inflammatory cells in hematoxylin
and eosin-stained cells or immuofluorescence analysis.
RNA extraction and quantitative RT-PCR
RNA from ascites fluid or peritoneal lavages was isolated
using the RNeasy Mini kit (Qiagen, Valencia, CA). DNase-
treated samples were subjected to real-time PCR using
SYBR Green PCR Master Mix (Applied Biosystems, Foster
City, CA). Steady-state mRNA levels of the M1 macro-
phage mark, CC chemokine ligand 3 (CCL3), and M2
macrophage mark, mannose receptor (mann-R) were ex-
pressed relative to corresponding GAPDH levels using the
comparative 2ΔΔCt method [31]. Relative expression values
were also normalized to levels of the epithelial marker
cytokeratin-18 (CK18) to account for the epithelial (tumor)





CC chemokine ligand 3 (CCL3): forward:
5′-TGCCCTTGCTGTTCTTCTCT-3′,
reverse: 5′–GATGAATTGGCGTGGAATCT-3′;






Processing, embedding and sectioning of formalin-fixed
ID8-NGL tumor tissue, and hematoxylin and eosin staining
for histology, were performed in The Allergy/Pulmonary &
Critical Care Med Division Immunohistochemistry Core
at Vanderbilt [32]. Immunofluorescent analysis of formalin-
fixed paraffin-embedded tumor tissue was performed using
standard deparaffinization and rehydration in 100%-90%-
80%-70% ethanol. To reduce tissue autofluorescence,
the samples were incubated in 0.5% Sudan Black in 70%
ethanol for 10 min, 70% ethanol without Sudan Black for10 min, and 50% ethanol for 2 min. The samples were
permeabilized in 0.4% Triton X-100 for 10 min and
subjected to antigen retrieval by boiling in 10 mM sodium
citrate for 7 min. The following primary antibodies
were used: rabbit polyclonal anti-Ki67/Mib-1 (Abcam,
Cambridge, UK; 1:200 dilution), goat polyclonal anti-GFP
(Abcam, 1:200), mouse monoclonal anti-pan-cytokeratin
(Abcam, 1:100), and rabbit polyclonal anti-phospho-p65
(serine 276) (Santa Cruz Biotechnology, Dallas, TX, 1:100.
Secondary antibodies used were goat anti-rat or -rabbit or -
mouse conjugated with Molecular Probes Alexa488 or
Alexa594 (Invitrogen). After staining with secondary
antibodies, the slides were washed 3 times with TBS-
Tween20, then washed once in TBS and then stained with
Molecular Probes TO-PRO-3 (Invitrogen) for 15 min
(1 μM in TBS). The slides were washed with TBS and the
coverslips mounted using Molecular Probes ProlongGold
antifade reagent (Invitrogen). Images were acquired using
an LSM 510 Meta confocal microscope in the Vanderbilt
University Medical Center Imaging Core.
For ascites fluid, macrophages and tumor cells were
identified by immunofluorescent staining for F4/80
(AbD Serotec; Raleigh, North Carolina, 1:200) and pan-
cytokeratin, respectively (Abcam, 1:1000) as described [32].
Secondary antibodies used were as described above. The
percentage of F4/80-positive/CK-negative cells was counted
in 3 separate fields at 40× using an immunofluorescent
microscope. At least 200 cells were counted per sample.
Immunohistochemical analysis of PAX8 and F4/80 ex-
pression in tumor tissue was performed as described [32],
using rabbit polyclonal anti-PAX8 (Proteintech, Chicago,
IL,1:50) and rat polyclonal anti-F4/80 (AbD Serotec; 1:50),
respectively.
Western blotting
Whole cell protein isolation, subcellular fractionation, west-
ern blotting and signal detection and quantification were
performed as described previously [33,34]. Primary anti-
bodies used were mouse monoclonal anti-GFP (Invitrogen),
mouse monoclonal anti-phospho-IκB (Cell Signaling Tech-
nology, Danvers, MA; 1:500), rabbit polyclonal anti-p65
(Cell Signaling Technology; 1:1000), mouse monoclonal
anti-histone H3 (Millipore; 1:1000) and anti-β-actin (Sigma;
1:10000).
Statistical analysis
Unless otherwise indicated, values shown for in vitro
experiments were the mean + SD of 3 independent experi-
ments, with comparison of groups performed by 2-tailed
Student’s t test. Comparison of groups in in vivo experi-
ments was performed by 2-tailed Mann-Whitney test. A
p value < 0.05 is considered statistically significant. The
relationship between BLI and indices of tumor burden
was analyzed by Spearman correlation.
Wilson et al. Journal of Ovarian Research 2013, 6:63 Page 5 of 11
http://www.ovarianresearch.com/content/6/1/63Results
Effects of stimulation or inhibition of NF-κB can be
quantified in ID8 mouse ovarian cancer cells stably
expressing the NF-κB reporter (ID8-NGL)
Mouse epithelial ovarian cancer (ID8) cells are a well-
established cell line derived from C57BL/6 mice that are
routinely used in syngeneic mouse models of ovarian
cancer [4,11,27,28]. Here, we generated ID8 cells stably
expressing an NF-κB-dependent reporter plasmid, termed
ID8-NGL. The NGL plasmid expresses a green fluorescent
protein (GFP)/luciferase fusion product under the control
of a synthetic NF-κB dependent promoter with a total of 8
NF-κB binding sites [25,26] (Figure 1A). As expected in
this tumor cell line, we confirmed detectable baseline
levels of luciferase activity (Figure 1B&C) and GFP expres-
sion (Figure 1D) in ID8-NGL cells compared to parental
ID8 cells. Lung tumor cells (A549-NGL) carrying the same
reporter construct were used as a positive control.
To test the ability to measure NF-κB responses, ID8-
NGL cells were treated with known activators of NF-κB,
TNF-α and IL-1β. Both activators stimulated a significant
increase in luciferase activity in protein extracts compared
to controls after 4 hours’ treatment (p < 0.01, Student’s t
test) (Figure 1E). Results were supported by biolumines-
cence imaging of cell monolayers (Figure 1F). We then
demonstrated the specificity of this effect by the abroga-
tion of TNF-α-mediated stimulation of luciferase activity
and GFP expression by 2 hours pre-treatment with the
NF-κB inhibitor, thymoquinone (TQ) (Figure 1F&G). In
addition, western blot analysis was consistent with the
known ability of TQ to inhibit TNF-α induction of IκB
phosphorylation (Figure 1F).Intra-peritoneal injection of ID8-NGL cells produces
ascites and peritoneal carcinomatosis in mice
The parental ID8 cell line for the ID8-NGL cells has
been shown to model the features of advanced serous
ovarian cancer with the development of malignant, bloody
ascites and peritoneal carcinomatosis [27,28,35]. Here, we
confirmed that ID8-NGL cells form a similar pattern of
ascites and peritoneal spread in our syngeneic model. By
90 days after tumor injection, mice developed prominent
abdominal distension indicative of ascites (Additional
file 1: Figure S1A). This was consistent with markedly
increased body weight and abdominal girth observed in
mice at this time point compared to PBS-injected controls
(Additional file 1: Figure S1B&C). Careful dissection of
the peritoneal cavities revealed that tumor cell-injected
mice displayed a reproducible pattern of tumor dissemin-
ation. As shown in Additional file 1: Figure S1D tumor
nodules were detected embedded in the peritoneal
wall (yellow arrows), and in the mesentery of the in-
testines (white arrows). A representative tumor implantin the smooth muscle of the peritoneal wall is shown in
Additional file 1: Figure S1E.
Increased NF-κB activity is detected during progressive
ovarian cancer dissemination in the peritoneal cavity
First, we confirmed that mice injected with ID8-NGL
cells displayed high levels of luminescence compared to
PBS-injected mice by bioluminescence imaging. Repre-
sentative images are shown in Figure 2A. When region
of interest analysis was performed to quantify abdominal
luminescence, ID8-NGL-injected mice displayed approxi-
mately 100-fold higher levels than non-injected controls
(average of 3.7 ± 2.3 × 107 RLU over the 30, 60 and 90 day
time points examined compared to 0.013 ± 0.009 × 107
RLU, respectively, p < 0.001, Mann-Whitney test), indicat-
ing the specificity of the signal. NF-κB reporter activity
increased in a time-dependent manner (Figure 2B), which
showed correlation with indices of tumor burden such as
mesenteric tumor mass and ascites volume at 90 days
(Figure 2C&D). To differentiate between specific increases
in NF-κB activity in tumor cells and an overall increase
in NF-κB signal due to increased tumor burden, we
performed luciferase assays of snap-frozen tumor tissue.
As shown in Figure 2E, there was a specific increase in
NF-κB activity within tumor tissue (when corrected for
cellular protein) in later phases of peritoneal tumor
spread. We confirmed this observation independently of
the NF-κB reporter by measuring levels of p65 in nuclear
extracts from harvested mesenteric tumors. As shown in
Figure 2F&G, the highest levels of nuclear p65 expression
were observed in 90 day tumors.
Peritoneal implants formed by ID8-NGL cells have
characteristics representative of high-grade serous
epithelial ovarian cancer
To determine if ID8-NGL tumors were representative
of high-grade serous epithelial ovarian cancer, we first
performed H&E staining and confirmed that tumors
displayed the characteristic morphology of high-grade
serous cancer (Figure 3A). Furthermore, we stained tu-
mors for expression of PAX8, an established marker of
high-grade serous ovarian tumors [36]. We found strong
nuclear immunoreactivity for PAX8 in epithelial tumor
cells, but not in the stroma, as confirmed by staining
for the epithelial marker, cytoplasmic pan-cytokeratin
(Figure 3B&C). Macrophage infiltration in stromal areas of
the tumor was also demonstrated by staining with F4/80, a
marker of mature macrophages (Figure 3D).
We then performed immunofluorescent analyses of
molecular markers of proliferation, NGL reporter expres-
sion, and NF-κB signaling in the epithelial component of
tumors. Staining for Ki67/mib-1 demonstrated that the tu-
mors were highly proliferative (Figure 3E). Activity of the
NGL reporter in tumors was shown by detection of the
Figure 2 NF-κB reporter activity increases during ovarian cancer progression. (A) Representative BLI of WT mice injected with ID8-NGL cells or
PBS (non-inject) over 90d following injection showing NF-κB reporter signal in tumor cells. Quantification of BLI in the abdominal cavity is shown in
(B). BLI was significantly correlated with (C) mesenteric tumor mass and (D) volume of ascites at 90d (Spearman). (E) Luciferase activity of the NF-κB
reporter was measured in harvested tumors and expressed relative to cellular protein. (F) Western blot analysis of p65 in nuclear extracts from harvested
tumors. Equal loading was shown by probing for the nuclear-specific protein, histone H3. (G) Nuclear p65 expression relative to corresponding histone
H3 levels was measured by densitometry. Values shown are mean + SD from 5 mice per group. ** p < 0.01 relative to 30d or 60d, Mann-Whitney test.
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and NF-κB activity in tumors was independently confirmed
by analysis of nuclear expression of phosphorylated-p65
(serine 276) (Figure 3G). We then demonstrated that
phospho-p65 and Ki67 were co-expressed in the nuclei of
a subset of tumor cells, but that there was minimal overlap
between the two within the nuclei (Figure 3H). This is
consistent with the localization of Ki67 to ribosomal
RNA-encoding nucleoli in proliferating cells [37].
Populations of monocytes and mature macrophages
increase in association with tumor load within the
peritoneal cavity
To assess the composition of peritoneal cell populations
prior to the development of ascites and during early phases
of peritoneal spread, we performed peritoneal lavages with
sterile PBS to collect cells from injected mice or control
non-injected mice. Cytospin counts of H&E-stained slides
revealed large cell clusters without definable borders
consistent with tumor cells in the peritoneal fluid (see
arrows in Figure 4A), which were excluded from our
inflammatory cell counts. Mononuclear cells were the
predominant inflammatory cell population present in theperitoneal cavities of both non-injected and injected mice.
Furthermore, in injected mice mononuclear cells made up
consistently 90% or greater of the inflammatory cells har-
vested in ascites fluid or in peritoneal lavages irrespective
of duration of exposure to tumor cells (data not shown).
The overall number of mononuclear cells harvested was
elevated approximately 8-fold relative to non-injected
controls at 90 days in the presence of tumor cells and
with increasing duration of tumor spread (approximately
15-fold increase from the 30 day to 90 day time point in
injected mice) (Figure 4B). Since macrophages are a major
subset of mononuclear cells, and given the established role
of peritoneal macrophages in ovarian cancer progression
[4], we also performed immunofluorescent analysis of
ascites fluid to detect epithelial (tumor) cells and mature
macrophages with antibodies against pan-cytokeratin and
F4/80, respectively (Figure 4C). These analyses confirmed
that the tumor cells were a major component of ascites
fluid at later time points (Figure 4D), and that mature mac-
rophages account for at least 60% of the non-epithelial cells
present. Collectively, these results suggest an elevated
inflammatory response is associated with the presence
of tumor cells in the peritoneal cavity.
Figure 3 Molecular characterization of ID8-NGL tumors. (A) H&E stain of a representative area of ID8-NGL tumors. (B) Immunohistochemical
detection of the marker of high-grade serous ovarian tumors, PAX8. (C) Fluorescent microscopy showing expression of the epithelial marker
pan-cytokeratin (CK) expression relative to TO-PRO-3-stained nuclei. (D) Immunohistochemical detection of the mature macrophage marker,
F4/80, in tumor sections. High power (×100) confocal images of the representative tumor section showing immunofluorescent detection of
(E) the proliferation marker Ki67/mib-1, (F) the GFP reporter and (G) overlap of Ki67/mib-1 and phospho-p65 (serine 276) (red) in the epithelial
component of the tumor. TO-PRO-3-stained nuclei are in blue. (H) Co-expression of phospho-p65 (red) and Ki67/mib-1 (green) is observed in the
nuclei of a subset of cells. The panels on the right show merged images of the corresponding boxed areas for two representative nuclei.
Figure 4 Analysis of fluid collected from the peritoneal cavity. (A) Representative images of cytospin analyses of peritoneal lavage fluid/ascites
collected from mice injected with tumor cells (Inject) or mock-PBS-injected mice (Non). Tumor cell clumps are shown (yellow arrow). (B) Overall
number of mononuclear cells collected increased in mice with tumors and with duration of progression. (C) Expression of the epithelial marker,
pan-cytokeratin (CK; red), and the mature macrophage marker, F4/80 (green), in ascites fluid on cytospin slides. Percentage of CK-positive cells is
shown in (D). Values are mean + SD of counts from 200 cells from each of 3 mice per group. * p < 0.01 relative to non-inject, Mann-Whitney test.
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Figure 5 Elevation of M2 macrophage marker in tumor-bearing mice. QPCR analysis of the mRNA expression of the markers of (A) M2
macrophages, mannose-receptor (mann-R) and (B) M1 macrophages, CCL3, in RNA extracted from peritoneal lavages or ascites fluid. Values were
normalized to corresponding levels of GAPDH mRNA expression and also CK18 mRNA levels, to account for epithelial content. The expression
ratio of mann-R to CCL3 is shown in (C). Values are mean + SD for 3 mice per group. * p < 0.01 relative to non-injected mice, Mann-Whitney test.
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anti-tumor M1 and pro-tumor M2 macrophages in RNA
extracted from peritoneal lavage fluid or ascites. CC che-
mokine ligand 3 (CCL3) and mannose-receptor (mann-R)
are well-established markers of M1 and M2 macrophages,
respectively [38]. Expression of mann-R, was significantly
increased in injected mice compared to non-injected con-
trols at both the 30 day and 90 day time points, with an
approximately 20-fold increase at 90 days (Figure 5A).
There was a markedly smaller increase in CCL3 ex-
pression at 90 days in tumor-bearing mice (approxi-
mately 5-fold), with no significant difference observed
at 30 days (Figure 5B). Consistent with these observations,
the ratio of mann-R to CCL3 expression was significantly
higher in injected mice at both time points (Figure 5C).
Reduced NF-κB activity in tumors is associated with reduced
expression levels of mannose-receptor in ascites fluid
To determine whether modulation of NF-κB activity in
tumors could alter the macrophage characteristics in
ascites fluid, we treated ID8-NGL-injected mice with theFigure 6 Thymoquinone reduces NF-κB activity in tumors and expressi
concentrations of TQ on NF-κB reporter activity in ID8-NGL cells after 24 hour
treatment with 20 mg/kg TQ or PBS vehicle (thrice weekly IP injections) on N
the mRNA expression of the markers of M2 macrophages, mannose-receptor
lavages. Values were normalized to corresponding levels of GAPDH mRNA ex
The expression ratio of mann-R to CCL3 is shown in (D). Values are mean + SDNF-κB inhibitor, thymoquine (TQ). Initial validation experi-
ments confirmed that there was a concentration-dependent
reduction in NGL reporter activity in ID8-NGL treated
with TQ in vitro (Figure 6A). 30 days after ID8-NGL
injection, mice were injected IP with TQ or PBS vehicle
thrice weekly for 10 days. Because of the limited amount
of macroscopic tumor observed at the time of sacrifice, we
were unable to accurately quantify drug effects on tumor
burden. Furthermore, as expected, no ascites was observed
at this relatively early stage of tumor progression. We prior-
itized snap-freezing tumors for luciferase assays, and deter-
mined that TQ treatment reduced NGL reporter activity by
approximately 25% in tumors in luciferase assays compared
to vehicle-treated tumors (Figure 6B).
Reduced NF-κB activity with TQ treatment was associ-
ated with significantly reduced levels of the M2 macro-
phage marker mann-R (48.3 ± 5.1% compared to vehicle,
p < 0.02, Mann-Whitney test) (Figure 6C) in peritoneal
lavage fluid, reflected in a significant reduction in the
mannR:CCL3 expression ratio (Figure 6D). Therefore,
this study provides evidence that macrophage populationson of M2 macrophage marker in ascites fluid. (A) Effects of increasing
s’ treatment as measured in luciferase assays. (B) Effect of 10 days
F-κB reporter activity in harvested ID8-NGL tumors. (C) QPCR analysis of
(mann-R) and M1 macrophages, CCL3, in RNA extracted from peritoneal
pression and also CK18 mRNA levels, to account for epithelial content.
for 5 mice per group. * p < 0.01 relative to vehicle, Mann-Whitney test.
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reducing NF-κB activity in tumor cells.
Discussion
In this study, we have modified the ID8 syngeneic mouse
model of ovarian cancer to allow intra-vital tracking of
NF-κB activity, known to play a critical role in development
of ascites and peritoneal dissemination [4,13-16], during
tumor progression. The ID8-NGL reporter cells are an
important tool for building upon our knowledge of the
role of NF-κB in ovarian cancer spread, including the link
between NF-κB activity in tumors and recruitment of host
immune macrophages within the peritoneal cavity. The
relationship between tumor progression and the immune
system cannot be fully addressed by clinically useful xeno-
graft models of human ovarian cancer, because those
models require the use of immunocompromised mice.
Therefore, the ID8-NGL immunocompetent model has
potential clinical relevance because the development of as-
cites, peritoneal carcinomatosis and macrophage infiltrates
recapitulate advanced human ovarian cancer [27,28,35].
Here, we show that ID8-NGL reporter cells show the
appropriate response to NF-κB activation and inhibition
in vitro, and to the NF-κB inhibitor, TQ, in vivo. We
have also demonstrated that there was markedly increased
NF-κB activation in ID8-NGL cells during the later stage
of tumor progression, which was associated with rapid
ascites accumulation and tumor dissemination. Further-
more, NF-κB activation was directly associated with cell
proliferation in a subset of tumor cells in vivo. These results
are consistent with previously published results [12,39,40].
We were unable to independently confirm our in vivo bio-
luminescence results by fluorescent imaging of ID8-NGL
tumors, due to insufficiently strong GFP fluorescence of the
fusion reporter protein. However, GFP expression was de-
tectable by alternative techniques, such as western blot and
indirect immunofluorescence, and these results were con-
sistent with our bioluminescence and luciferase assay data.
While other groups have focused on immune cell infil-
tration into tumors [22-24], we studied the immune cell
population in ascites and peritoneal lavage fluid. We found
that macrophages dominate the immune cell population in
the peritoneal cavity, and the number of macrophages
increases in parallel with the progression of ascites and
peritoneal tumor dissemination. Furthermore, M2 and to
a lesser extent M1 markers of tumor-associated and cyto-
toxic macrophage phenotypes, respectively, increase with
peritoneal tumor spread in ovarian cancer. An area of on-
going investigation is to determine how activity of NF-κB
in tumor cells influences macrophages and macrophage
phenotypes in promoting ovarian cancer spread. We believe
that this ID8-NGL model serves as an important system
for addressing this question. As proof-of-principle, we
demonstrated that chemical reduction of NF-κB activityin tumors was associated with reduced levels of the M2
macrophage mark, mannose-receptor, in ascites fluid.
Although specific inflammatory cell populations were not
dissected, these results provide evidence that macrophage
populations may be shifted towards an “anti-tumor”
M1 phenotype by reducing tumor NF-κB activity with
a systemic NF-κB inhibitor. Furthermore, the ID8-NGL
model could serve as a powerful tool for pre-clinical testing
of agents that target NF-κB, such as TQ, in future interven-
tion studies.
We acknowledge that a limitation of our NF-κB-linked
reporter model is that bioluminescent imaging does not
provide a direct measure of the total number of tumor
cells, in contrast to imaging of tumors derived from
ID8-Luc cells, which have constitutive stable expression
of the luciferase reporter [4]. However, luciferase assays
on harvested tumors where cellular content can be
normalized confirmed strongly increased NF-κB reporter
activity at late-stage progression. This suggests that add-
itional insight can be gained by comparison of live imaging
with data from isolated tumor cell populations. Other
non-invasive imaging modalities, performed in parallel
to bioluminescence imaging, such as microPET/CT or
intra-vital imaging of fluorescent dyes [35], are alternative
options to match NF-κB activity with tumor burden in the
ID8-NGL model.
Conclusions
We have generated mouse ID8 ovarian cancer cells stably
expressing the NGL NF-κB reporter plasmid to track
NF-κB activity in a syngeneic mouse model. The strengths
of this model are (i) the capacity to evaluate the role of
NF-κB activity in mediating the link between cancer
progression and the immune system in ovarian cancer,
and (ii) the ability to measure NF-κB activity through a
dual luciferase -GFP fusion protein, allowing multiple
independent assays to confirm changes in NF-κB activity
in living animals and in harvested tumors. Additional appli-
cations for this model include pre-clinical development
of drugs that target NF-κB, such as NF-κB inhibitors, in
ovarian cancer.
Additional file
Additional file 1: Figure S1. Peritoneal dissemination of ID8-NGL cells
during tumor progression. (A) Mice injected with ID8-NGL cells show
distended abdomen indicative of ascites formation at 90d after injection
compared to PBS-injected mice (non-inject). Changes in (B) body weight
and (C) abdominal girth were measured. Values are mean + SD for 5 mice
per group. (D) Mice injected with ID8-NGL cells display abdominal
dissemination of tumor cells. The main sites of tumor implantation are
the peritoneal wall (yellow arrows) and in the mesentery (white arrow).
(E) H&E staining example of tumor implantation in the peritoneal wall.
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